Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 3556 AL 3570

The Role of Biomarkers in Alzheimer's Disease Drug Development

Cummings J.

Adv Exp Med Biol. 2019;1118:29-61. doi: 10.1007/978-3-030-05542-4_2.

The Alzheimer Precision Medicine Initiative

Hampel H, Vergallo A, Perry G, Lista S; Alzheimer Precision Medicine Initiative (APMI).

J Alzheimers Dis. 2019;68(1):1-24. doi: 10.3233/JAD-181121.

Rationale and Design of a Clinical Trial of Adapted Tango to Improve Negative Health Impacts in Middle Aged African-American Female Caregivers of Persons with Alzheimer's Disease (ACT Trial)

Hackney ME, McCullough LE, Bay AA, Silverstein HA, Hart AR, Shin RJ, Wharton W.

J Alzheimers Dis. 2019;68(2):767-775. doi: 10.3233/JAD-181130.

Clinical and biological effects of long-term lithium treatment in older adults with amnestic mild cognitive impairment: randomised clinical trial

Forlenza OV, Radanovic M, Talib LL, Gattaz WF.

Br J Psychiatry. 2019 Nov;215(5):668-674. doi: 10.1192/bjp.2019.76.

Extracellular Vesicle Biomarkers Track Cognitive Changes Following Intranasal Insulin in Alzheimer's Disease

Mustapic M, Tran J, Craft S, Kapogiannis D.

J Alzheimers Dis. 2019;69(2):489-498. doi: 10.3233/JAD-180578.

Nanowired delivery of cerebrolysin with neprilysin and p-Tau antibodies induces superior neuroprotection in Alzheimer's disease

Sharma HS, Muresanu DF, Castellani RJ, Nozari A, Lafuente JV, Tian ZR, Ozkizilcik A, Manzhulo I, Mössler H, Sharma A.

Prog Brain Res. 2019;245:145-200. doi: 10.1016/bs.pbr.2019.03.009. Epub 2019 Apr 2.

Plasmalogens and Alzheimer's disease: a review

Su XQ, Wang J, Sinclair AJ.

Lipids Health Dis. 2019 Apr 16;18(1):100. doi: 10.1186/s12944-019-1044-1.

Advancing Alzheimer's Disease Treatment: Lessons from CTAD 2018

Vellas B, Bain LJ, Touchon J, Aisen PS.

J Prev Alzheimers Dis. 2019;6(3):198-203. doi: 10.14283/jpad.2019.11.

Target engagement in an alzheimer trial: Crenezumab lowers amyloid β oligomers in cerebrospinal fluid

Yang T, Dang Y, Ostaszewski B, Mengel D, Steffen V, Rabe C, Bittner T, Walsh DM, Selkoe DJ.

Ann Neurol. 2019 Aug;86(2):215-224. doi: 10.1002/ana.25513. Epub 2019 Jun 22.

Transcranial magnetic stimulation: Emerging biomarkers and novel therapeutics in Alzheimer's disease

Koch G, Martorana A, Caltagirone C.

Neurosci Lett. 2020 Feb 6;719:134355. doi: 10.1016/j.neulet.2019.134355. Epub 2019 Jun 28.

MIND food and speed of processing training in older adults with low education, the MINDSpeed Alzheimer's disease prevention pilot trial

Clark DO, Xu H, Moser L, Adeoye P, Lin AW, Tangney CC, Risacher SL, Saykin AJ, Considine RV, Unverzagt FW.

Contemp Clin Trials. 2019 Sep;84:105814. doi: 10.1016/j.cct.2019.105814. Epub 2019 Jul 18.

The "rights" of precision drug development for Alzheimer's disease

Cummings J, Feldman HH, Scheltens P.

Alzheimers Res Ther. 2019 Aug 31;11(1):76. doi: 10.1186/s13195-019-0529-5.

Developing Effective Alzheimer's Disease Therapies: Clinical Experience and Future Directions

Elmaleh DR, Farlow MR, Conti PS, Tompkins RG, Kundakovic L, Tanzi RE.

J Alzheimers Dis. 2019;71(3):715-732. doi: 10.3233/JAD-190507.

A Pilot Study of Exenatide Actions in Alzheimer's Disease

Mullins RJ, Mustapic M, Chia CW, Carlson O, Gulyani S, Tran J, Li Y, Mattson MP, Resnick S, Egan JM, Greig NH, Kapogiannis D.

Curr Alzheimer Res. 2019;16(8):741-752. doi: 10.2174/1567205016666190913155950.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias